Finoriq research workspace
Aquestive Therapeutics, Inc. (AQST) SEC Filings & Filing Highlights
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States. Review AQST SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
- Company
- Aquestive Therapeutics, Inc. (AQST)
- Ticker
- AQST
- Market Cap
- $497.5M
- Latest Price
- $3.965
- Industry
- Biotech & Pharma
Aquestive Therapeutics, Inc. (AQST) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Aquestive Therapeutics, Inc. (AQST).
| Event | Form | Date |
|---|---|---|
| Aquestive Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 10, 2026(a) Aquestive Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 10, 2026 | 8-K5.07 | 2026-06-10 |
| Aquestive Therapeutics Reports First Quarter 2026 Financial ResultsAquestive Therapeutics Reports First Quarter 2026 Financial Results | 8-K7.01 | 2026-05-13 |
| Aquestive Therapeutics, Inc.: Securities issuanceIn connection with entering into the Credit Agreement, the Company entered into a warrant issuance agreement (the “Warrant Issuance Agreeme... | 8-K3.02 | 2026-05-13 |
| Debt or FinancingDebt or Financing | 8-K2.03 | 2026-05-13 |
| Aquestive Therapeutics Reports First Quarter 2026 Financial ResultsAquestive Therapeutics Reports First Quarter 2026 Financial Results | 8-K2.02 | 2026-05-13 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.